Vaxart Inc (NASDAQ: VXRT) — Healthcare · Share Price, Chart & Market Data
About: Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.72 (-2.70%)
VXRTVaxart Inc
Loading watchlist status…
Trade VXRT now
Vaxart Inc share price
VXRT price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 9:03 am GMT+0
VXRT price performance
-5.263%
5D
10.769%
1M
100%
YTD
61.002%
1Y
VXRT price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 9:03 am GMT+0
VXRT details
VXRT Market Signals